Shares of IDEAYA Biosciences Inc. (IDYA) are up over 10% at $30 in premarket trading on Monday, following positive interim data from the OptimUM-09 trial.
OptimUM-09 is a phase II trial evaluating the company's lead oral drug candidate, Darovasertib, in the neoadjuvant setting of primary uveal melanoma.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com